革兰阳性球菌感染抗菌治疗进展
[11].BorekAP PetersonLR NoskinGA. Activity of linezolid against medically importmlt gram-positive haeteria from 1997 to 1999(C). 40th ICAAC Abstract 12299 Toronto Ontario Canada 2000.
[12].Johnson A P Warner M, Livermore D M. Activity of bnczolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United KingdomkJJ. JAntimiemhChemmther 2000 45225 230.
[I3].TumakMR ForrestA HyattJM etal. Multiple-dosephr-cokinetics of linevolld 200 400 and 600rug PO ql2h. 38th 1-CAAC Abstract Al5 San Frmcism U. S. A 1999.
[14].Hartmam CS LeachTS KajaRJ etal. Linezolid in the treatment of vanconlycin resistant Enterococcus:a dose comparative multicenter phase III trial(C). 40th ICAAC Abstract MN-2235 Toronto Ontario Canada 2000.
[15].Cammarata S K Wunderink R G Hempsall K A et al. Efficacy of linezolid in patients with nosccomial Pneumonia based on severity of illness as determined by baseline APACHE BT score LCJ. 40th ICAAC Abstract M N-2234 Toronto Ontario Canada 2000.
[16].MoisePA BimlinghamMC Eo=estA etal. Linezolid use in patients who are intolerant to or fall vaneomycinLCJ. 40th I CAACAbstractM N-2233 Toronto Ontaxio Canada 2000.
[17].Bruss J B Sagth L G Duvall S E et al. Safety and Toleranceof linezolid, adverse events reported in phase [I] lrialsLCJ. 40th ICAAC Abstract M N-2236 Toronto Ontario Canada2000.
[18].KucersA CroweSM GraysonML etal. The Use of An-tibioitcs 5th edLMJ. Oxford' Buttel'wooh-Heinemann A Di-vision of Read Educational and Professional Publishing Ltd 1997 791 801.
[19].Johnson AP. LY-3333281JJ. Curt Opin Anti infect Invest Drugs 1999 1'87 95.
[20].Snydman DR Jaeobus .NV McDermott et al. Comparative in vitro activities of daptamyein and vaneommyein against resistant gram-positive pathogens(J) Antimicroh Agents Chemother 2000 44:3447-3450.
[21].Woodworth JR Nyhart E H Brier G L et al. Single-dosepbarmacokinetics and antibacterial activity of daptomycin a newlipopeptide antibiotic in healthy volunteersLJJ. Antimiemb Agents Chemother 1992 30'318 325.
[22].Tally FP DeBruin M F. development of daptomycin for gram-positive infectious(J).J Antimicvab Chemother 2000 46:523-526.
[23].PetersenPJ JacobusNV WeissWJ et ab ln vitro aud in vi-vo antibacterial activities of a novel glycyleyeline the 9-t-butyl- glycylamido derivative of minocyclinetGAR-936)LJ. Antimi- cob Agents Chemother 1999 43' 738-744.
[24].Mercier R C Kennedye Meadows C. Activities of GAR 936 alone and in combination versus multi-drug resistant Staphylococcus aureus and Enterococcus faciumL(C) 40th ICAAC Abstract E532 Toronto Ontario Canada 2000.
[25].Sum P Petersen P J. Synthesis and antibacterial activity of nov- el tetracycline and glyeylcycline derivativesLCJ, 40th ICAACAbstract F2200 Toronto Ontario Canada 2000.
